Arcus Biosciences, Inc.

Healthcare · Biotechnology · United States

Last price 18.61 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.68B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2α inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in...